Regeneron Pharmaceuticals (REGN) Projected to Announce Quarterly Earnings on Friday

Regeneron Pharmaceuticals (NASDAQ:REGN) is expected to release its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to announce earnings of $16.36 per share and revenue of $4.56 billion for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, October 30, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the company posted $12.81 earnings per share. The company’s revenue was up 16.7% compared to the same quarter last year. On average, analysts expect Regeneron Pharmaceuticals to post $49.10 EPS for the current fiscal year and $53.12 EPS for the next fiscal year.

Regeneron Pharmaceuticals Price Performance

REGN opened at $813.27 on Thursday. The stock has a 50-day moving average price of $791.72 and a 200-day moving average price of $737.14. Regeneron Pharmaceuticals has a 12-month low of $591.52 and a 12-month high of $859.34. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $83.73 billion, a P/E ratio of 20.10, a PEG ratio of 1.36 and a beta of 0.16.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. Evercore increased their price target on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. The Goldman Sachs Group lifted their price objective on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Raymond James Financial upped their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Jefferies Financial Group boosted their price target on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $847.90.

Insiders Place Their Bets

In related news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the sale, the executive vice president owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock worth $6,506,845 in the last ninety days. Insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.